Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Apimeds Pharmaceuticals US Inc (APUS)

Apimeds Pharmaceuticals US Inc (APUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 17,477
  • Shares Outstanding, K 12,576
  • Annual Sales, $ 0 K
  • Annual Income, $ -1,390 K
  • EBIT $ -5 M
  • EBITDA $ -5 M
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.39

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9510 +46.13%
on 02/13/26
3.0000 -53.68%
on 01/23/26
-0.2903 (-17.28%)
since 01/20/26
3-Month
0.9510 +46.13%
on 02/13/26
3.3200 -58.14%
on 12/01/25
-1.0103 (-42.10%)
since 11/20/25

Most Recent Stories

More News
Apimeds Pharmaceuticals and Lōkahi Therapeutics Announce FDA Type C Meeting Scheduled for LT‑100 (Apitox)

Apimeds Pharmaceuticals US, Inc. and Lōkahi Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) Division of Anesthesiology, Addiction Medicine and Pain Medicine (DAAP)...

APUS : 1.3897 (-10.34%)
Apimeds Pharmaceuticals and MindWave Innovations Announce Closing of $100MM PIPE Financing and Activation of 1,000 Bitcoin to Power AI-Driven Yield Generation Strategy

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) today announced the closing of its previously announced $100 million private investment in public equity (PIPE) financing. This substantial investment...

APUS : 1.3897 (-10.34%)
Apimeds and MindWave Announce Merger, Integrating Biotech Growth with AI-Driven Digital Treasury Yield Generation Backed by $100M PIPE

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) announced a merger with MindWave Innovations Inc, uniting Apimeds’ late-stage, non-opioid pain-management biologic portfolio with MindWave’s AI-driven...

APUS : 1.3897 (-10.34%)
Apimeds Brings ai² Futures Lab™ to the Palouse — Partnering with the University of Idaho to Shape the Future of Biotech Innovation

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the expansion of its ai² Futures Lab™ program through a new collaboration with the University of Idaho College...

APUS : 1.3897 (-10.34%)
Apimeds Pharmaceuticals says “I love my Ducks” with new ai² Futures Lab™ Program collaboration with the University of Oregon’s Lundquist College of Business

Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) (“Apimeds”) today announced the expansion of the Apimeds ai ² Futures Lab program through a new collaboration...

APUS : 1.3897 (-10.34%)
Apimeds Expands ai² Future Labs Program to Include University of San Diego Students in Biotech Business Development

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the expansion of its ai² Future Labs program by engaging graduate students from the University of San Diego’s Knauss...

APUS : 1.3897 (-10.34%)
Apimeds Welcomes FDA Draft Guidance as Catalyst for Advancing Apitox Non-Opioid Pain Program

Apimeds Pharmaceuticals US, Inc. (NYSE: APUS) today welcomed the U.S. Food and Drug Administration’s (FDA) newly released draft guidance on the development of non-opioid pain therapies, highlighting...

APUS : 1.3897 (-10.34%)
Apimeds Pharmaceuticals US, Inc. Partners with University of Alabama to Advance Biotech Business Development via ai² Future Labs

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds”) today announced the launch of its ai² Future Labs program in partnership with The University of Alabama Culverhouse...

APUS : 1.3897 (-10.34%)
Apimeds Expands Leadership Team with Dr. Susan Kramer to Lead Product Development and Brian Peters to Lead its ai² Division

Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) (“Apimeds” or the “Company”), a clinical-stage biopharmaceutical company developing Apitox , an intradermally administered,...

APUS : 1.3897 (-10.34%)
D. Boral Capital Acted as Sole Bookrunner to Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) in connection with its $13.5 Million Initial Public Offering

NEW YORK CITY, NY / ACCESS Newswire / May 16, 2025 / On May 12, 2025, Apimeds Pharmaceuticals US, Inc. (NYSE:APUS) ("Apimeds" or the "Company"), a clinical stage biopharmaceutical company that is in the...

APUS : 1.3897 (-10.34%)

Business Summary

Apimeds Pharmaceuticals US Inc. operates as a clinical stage biopharmaceutical company. It researches, develops, manufactures, commercializes and sells Apitox, an active pharmaceutical ingredient for the treatment of inflammation and pain management symptoms associated with osteoarthritis and multiple...

See More

Key Turning Points

3rd Resistance Point 1.7753
2nd Resistance Point 1.6476
1st Resistance Point 1.5187
Last Price 1.3897
1st Support Level 1.2621
2nd Support Level 1.1344
3rd Support Level 1.0055

See More

52-Week High 4.0310
Fibonacci 61.8% 2.8544
Fibonacci 50% 2.4910
Fibonacci 38.2% 2.1276
Last Price 1.3897
52-Week Low 0.9510

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar